Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 3,019 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 3,019 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $209,397.84. Following the transaction, the insider directly owned 77,122 shares in the company, valued at $5,349,181.92. The trade was a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Eric Pauwels also recently made the following trade(s):

• On Monday, January 12th, Eric Pauwels sold 1,024 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.70, for a total transaction of $80,588.80.
• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total value of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.50, for a total value of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.43, for a total value of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Stock Up 1.1%

Shares of PTCT stock traded up $0.76 during trading hours on Friday, hitting $70.66. 2,532,077 shares of the company were exchanged, compared to its average volume of 1,290,685. The firm has a fifty day moving average of $75.01 and a 200 day moving average of $67.78. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The firm has a market cap of $5.67 billion, a PE ratio of 8.25 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same period last year, the company posted ($0.85) EPS. Analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on PTCT shares. TD Cowen restated a “hold” rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company dropped their price objective on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Bank of America reduced their target price on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a report on Friday. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.73.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company reported full‑year 2025 product and royalty revenue that exceeded guidance, strong early commercial uptake of Sephience™ (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M), and $1.95B cash on hand — supports runway for commercialization and R&D. Read More.
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but kept a “buy” rating, signaling continued analyst conviction and providing potential support for the stock. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript and highlights are available for investors parsing management commentary for drivers of the revenue miss (useful to judge one‑time items vs. sustained weakness). Read More.
• Negative Sentiment: Q4 results missed badly: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — revenue fell ~22.7% YoY. That miss is the primary near‑term driver of investor concern. Read More.
• Negative Sentiment: Management set FY‑2026 revenue guidance of $700M–$800M versus street consensus near $974M — a sizable downward gap that reduces near‑term upside and likely drove negative sentiment. Read More.
• Negative Sentiment: Regulatory uncertainty after PTC withdrew a Translarna NDA has prompted new questions about that program’s prospects and potential revenue contribution. Read More.
• Negative Sentiment: Insider selling: VP Mark Elliott Boulding sold ~5,894 shares across Feb. 17–18 (recent Form 4 filings), a modest but visible reduction that some investors view negatively. Read More.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PTCT. Vanguard Group Inc. boosted its holdings in PTC Therapeutics by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock valued at $668,691,000 after purchasing an additional 514,204 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of PTC Therapeutics by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after buying an additional 224,481 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of PTC Therapeutics by 28.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp grew its position in shares of PTC Therapeutics by 34.2% during the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after buying an additional 1,071,343 shares in the last quarter. Finally, Toronto Dominion Bank increased its stake in shares of PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.